Trial results published in a recent article indicate that patients using tiotropium in the early stages of chronic obstructive pulmonary disease (COPD) had better lung function and a slower decline in ...

Please provide your email address to receive an email when new articles are posted on . Daily tiotropium via the HandiHaler device improved lung function but did not reduce frequency of exacerbations ...

August 12, 2009 — Tiotropium added to inhaled corticosteroids (ICS) and, long-acting beta-agonists (LABA) in patients with chronic obstructive pulmonary disease (COPD) was associated with reduced ...

Please provide your email address to receive an email when new articles are posted on . Tiotropium used as an additional treatment to inhaled corticosteroids reduced airflow obstruction and improved ...

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for ...

Patients described in the following tiotropium clinical trials were at least 40 years of age, had a clinical diagnosis of COPD, had a baseline FEV 1 of less than 60-65% of predicted normal values, and ...

The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the ...

Asthma patients, who have recurring symptoms and exacerbations despite using the combination therapy of inhaled glucocorticoids and long acting beta-agonists (LABA), show significant improvement with ...

The fixed-dose combination of tiotropium and olodaterol (trade name: Spiolto Respimat) has been approved since July 2015 for maintenance treatment in adults with chronic obstructive pulmonary disease ...

Boehringer Ingelheim announced results from its Phase 3 UniTinA-asthma trial program evaluating tiotropium in adults, adolescents, and pediatric patients with different severities of asthma who remain ...

Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials ...